title: Comparison of efficiency of intravitreal ceftazidime and intravitreal cefepime in the treatment of experimental Pseudomonas aeruginosa endophthalmitis.
abstract: In this study, we evaluated the efficiency of cefepime in the treatment of experimental Pseudomonas aeruginosa endophthalmitis. We compared the findings with the standard dose of ceftazidime (1 mg/0.1 ml). Thirty-six New-Zealand White rabbits were divided into 6 equal groups and were treated with different methods (Group 1 = sham, Group 2 = 0.5 mg/0.1 ml cefepime, Group 3 = 1 mg/0.1 ml cefepime, Group 4 = 2 mg/0.1 ml cefepime, Group 5 = 1 mg/0.1 ml ceftazidime, Group 6 = control). The eyes of rabbits in each group were examined clinically on 1 st , 3 rd , and 6 th day of the experiment. At 6 th day, 0.1 ml vitreous humor aspirates were obtained and plated for quantification on the blood agar and the results were expressed as colony-forming unit/ml. Subsequently, the eyeballs were enucleated and the histopathological evaluation was performed. Our findings denoted beneficial effects of cefepime in treatment groups (especially, in Groups 3 and 4). Intravitreal cefepime may be an alternative drug in the treatment of P. aeruginosa endophthalmitis.
authors.affiliation: Department of Ophthalmology, School of Medicine, Firat University, Elazig, Turkey.
authors.forename: Nurettin
authors.initials: N
authors.lastname: Deniz
authors.forename: Orhan
authors.initials: O
authors.lastname: Aydemir
authors.forename: Mete
authors.initials: M
authors.lastname: Güler
authors.forename: Nusret
authors.initials: N
authors.lastname: Akpolat
authors.forename: Ahmet
authors.initials: A
authors.lastname: Kizirgil
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents; D000077723:Cefepime; D002442:Ceftazidime / Q000008:administration & dosage*; D002511:Cephalosporins / Q000008:administration & dosage*; D004195:Disease Models, Animal; D009877:Endophthalmitis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D015818:Eye Infections, Bacterial / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification*; D011817:Rabbits; D016896:Treatment Outcome; D014822:Vitreous Body / Q000382:microbiology* / Q000473:pathology
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000077723:Cefepime; D002442:Ceftazidime